Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, ...

In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...

Celltrion says its tocilizumab biosimilar, Avtozma, is commercially available to patients in the United States in ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Key opportunities in the drug delivery devices market include expanding digital health partnerships for innovative injectable and connected solutions, addressing chronic conditions like asthma and ...

Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio. To take over Surf, Halozyme is paying $300 ...

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (ABOS) (NASDAQ: ABOS) (“Acumen” or the “Company ...

MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...

Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026. ・The subcutaneous formulation of the drug VK2735 ...